# Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.

> **NCT00184626** · PHASE4 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 97 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** biphasic insulin aspart
- **DRUG:** insulin glargine
- **DRUG:** metformin

## Key facts

- **NCT ID:** NCT00184626
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09-10
- **Primary completion:** 2005-10-24
- **Final completion:** 2005-10-24
- **Target enrollment:** 97 (ACTUAL)
- **Last updated:** 2017-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00184626

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00184626, "Comparison of Insulin Glargine Versus Biphasic Insulin Aspart 30/70 or Biphasic Insulin Aspart 30/70 in Combination With Metformin in Subjects With Type 2 Diabetes.". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00184626. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*